Yan Leyfman: New Insights in CAR T-Cell Therapy for Multiple Myeloma
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn about a paper by Doris Hansen et al. published in Journal of Clinical Oncology:
“New Insights in CAR T-Cell Therapy for Multiple Myeloma!
The US Multiple Myeloma Immunotherapy Consortium compared idecabtagene vicleucel (ide-cel) vs. ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma (RRMM) across 19 institutions.
Key Findings:
Cilta-cel showed superior treatment responses, longer progression-free and overall survival.
Higher toxicity observed with cilta-cel: increased rates of grade ≥3 CRS, infections, second primary malignancies, and delayed neurotoxicity.
No significant differences in ICANS, overall CRS, severe cytopenia, or nonrelapse mortality.
These findings provide crucial real-world insights into the efficacy and safety of SOC CAR T-cell therapies in RRMM.”
Authors: Doris Hansen, Lauren Peres, Danai Dima, Krina Patel, Surbhi Sidana et al.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023